Corticosteroids alter CGRP and melatonin release in cluster headache episodes

Area of Science:

• Neurology
• Endocrinology
• Pain Medicine

Background:

• Calcitonin gene-related peptide (CGRP) is a key marker for trigeminal nerve activation in acute cluster headaches (CH).
• Altered melatonin production in CH patients suggests potential hypothalamic dysfunction.
• This study investigates the impact of short-term corticosteroid prevention on CGRP and melatonin in CH.

Purpose of the Study:

• To assess the effects of short-term corticosteroid therapy on CGRP and melatonin release in cluster headache patients.
• To determine if corticosteroids influence interictal activity in the trigeminal and hypothalamic systems.

Main Methods:

• Prospective observational cohort study involving episodic CH patients and multiple sclerosis controls.
• Administered intravenous methylprednisolone (MPD) followed by oral prednisone tapering.
• Measured plasma CGRP levels and urinary 6-sulfatoxymelatonin (aMT6s) before, during, and after corticosteroid treatment.

Main Results:

• Corticosteroid administration significantly decreased CGRP plasma levels in CH patients.
• Nocturnal aMT6s urine excretion significantly increased in CH patients during treatment.
• No significant changes in these biomarkers were observed in the control group.

Conclusions:

• Corticosteroids effectively alter CGRP and aMT6s levels during a cluster headache bout.
• These biomarker changes suggest corticosteroids may modulate trigeminal activation and hypothalamic dysfunction in CH.
• The findings support a potential therapeutic role for corticosteroids in managing cluster headaches.